Delving into the Latest Updates on RO-5469754 with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms

RO 5469754, RO5469754

Target-

Action-

Mechanism-

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

F. Hoffmann-La Roche Ltd.

Active Organization-

Inactive Organization

Hoffmann-La Roche, Inc.

License Organization-

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 523913563H

A Single-Center, Randomized, Observer-Blinded, Placebo-Controlled, Single-Ascending-Dose (SAD) Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5469754, a Humanized Monoclonal Antibody, Following Intravenous or Subcutaneous Administration in Healthy Adults - RO5469754 monoclonal antibody study

Start Date01 Nov 2011

Sponsor / Collaborator-

NCT01620931

/ CompletedPhase 1

A Single-Center, Randomized, Observer-Blinded, Placebo-Controlled, Single-Ascending-Dose (SAD) Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5469754, a Humanized Monoclonal Antibody, Following Intravenous or Subcutaneous Administration in Healthy Adults

This randomized, observer-blinded, placebo-controlled study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of RO5469754 in healthy volunteers. Subjects will be randomized in cohorts to receive single ascending intravenous or subcutaneous doses of RO5469754 or placebo. In-clinic period will be from Day -1 to Day 4, with a safety follow-up of 15 weeks after dosing.

Start Date07 Nov 2011

Sponsor / Collaborator

Hoffmann-La Roche, Inc.

100 Clinical Results associated with RO-5469754

Login to view more data

100 Translational Medicine associated with RO-5469754

Login to view more data

100 Patents (Medical) associated with RO-5469754

Login to view more data

100 Deals associated with RO-5469754

Login to view more data